NVAX Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings, Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of -95.02%. Novavax, Inc.'s return on equity of -- beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 32.19%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $35.25 which suggests that it could grow by 364.43%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Novavax, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Novavax, Inc..

Novavax, Inc. has a beta of 2.367, which suggesting that the stock is 136.738% more volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.17%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are larger than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Novavax, Inc.'s net income of -$202.4M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Novavax, Inc.'s price-to-earnings ratio is 5.51x while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.55x versus 2.42x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of 33.68%. Novavax, Inc.'s return on equity of -- beat Merck & Co., Inc.'s return on equity of 39.63%.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 32.19%. On the other hand Merck & Co., Inc. has an analysts' consensus of $115.11 which suggests that it could grow by 5.43%. Given that Novavax, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Novavax, Inc. is more attractive than Merck & Co., Inc..

Novavax, Inc. has a beta of 2.367, which suggesting that the stock is 136.738% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3% to investors and pays a quarterly dividend of $0.85 per share. Novavax, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Novavax, Inc.'s net income of -$202.4M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Novavax, Inc.'s price-to-earnings ratio is 5.51x while Merck & Co., Inc.'s PE ratio is 14.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.55x versus 4.31x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of -19.69%. Novavax, Inc.'s return on equity of -- beat Moderna, Inc.'s return on equity of -30.18%.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 32.19%. On the other hand Moderna, Inc. has an analysts' consensus of $37.40 which suggests that it could fall by -27.9%. Given that Novavax, Inc. has higher upside potential than Moderna, Inc., analysts believe Novavax, Inc. is more attractive than Moderna, Inc..

Novavax, Inc. has a beta of 2.367, which suggesting that the stock is 136.738% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Novavax, Inc.'s net income of -$202.4M is lower than Moderna, Inc.'s net income of -$200M. Notably, Novavax, Inc.'s price-to-earnings ratio is 5.51x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.55x versus 9.00x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of 21.32%. Novavax, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.

Novavax, Inc. has a consensus price target of $12.89, signalling upside risk potential of 32.19%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 9.8%. Given that Novavax, Inc. has higher upside potential than Pfizer Inc., analysts believe Novavax, Inc. is more attractive than Pfizer Inc..

Novavax, Inc. has a beta of 2.367, which suggesting that the stock is 136.738% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.59% to investors and pays a quarterly dividend of $0.43 per share. Novavax, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Novavax, Inc.'s net income of -$202.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Novavax, Inc.'s price-to-earnings ratio is 5.51x while Pfizer Inc.'s PE ratio is 15.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.55x versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.